Histotripsy for liver cacners and mets.
The literature supporting histotripsy in various cancers is limited. Histotripsy is a new technology that was approved in 2023 by the Food and Drug Administration (FDA) for the treatment of liver tumors. It uses focused ultrasound energy to destroy tumors non-invasively — that is, nonsurgically. There is no long-term data for histotripsy. It seems to be effective in treating the targeted tumors. While it can produce responses, long -term improvement in survival is not known.
Mishal Menderatta-Lala et al, The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors.Vascular and Interventional Radiology, Sep 3 2024
Singh MP, Sethuraman SN, Miller C, Malayer J, Ranjan A. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors. Theranostics. 2021 Jan 1;11(2):540-554. doi: 10.7150/thno.49517. PMID: 33391491; PMCID: PMC7738858.
Jan Vidal-Jove et al, First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. d.
INTERNATIONAL JOURNAL OF HYPERTHERMIA 2022, VOL. 39, NO. 1, 1115–1123